drugset / Trial / NCT00362115
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
Timeline
- Start
- 2006-05
- Primary completion
- 2006-12
- Completion
- 2006-12
Outcome
Met primary endpoint
registry Azilsartan Medoxomil 10 mg QD vs Placebo QD; p = 0.0008; Mean Difference (Final Values) -5.3 (95% CI -8.33 to -2.20) NCT00362115 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azilsartan medoxomil | Other / unclassified | 5 mg | Oral |
| Subject | Azilsartan medoxomil | Other / unclassified | 10 mg | Oral |
| Subject | Azilsartan medoxomil | Other / unclassified | 20 mg | Oral |
| Subject | Azilsartan medoxomil | Other / unclassified | 40 mg | Oral |
| Subject | Azilsartan medoxomil | Other / unclassified | 80 mg | Oral |
| Comparator | Olmesartan | Other / unclassified | 20 mg | Oral |